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Purpose: Glaucoma is an optic neuropathy characterized by a high intraocular pressure (IOP), alterations in optic nerve
head, and loss of visual field that could lead to bilateral blindness. Serotonin (5-HT) is a biogenic monoamine that is
synthesized from hydroxylation of tryptophan and acts by three ways, dissemination, metabolism, and reuptake in synaptic
cleft through specific systems of the membrane. The purpose of this study is to evaluate the 5-HT and 5-HIAA (5-
hydroxiindolacetic acid) levels in the aqueous humor of patients with primary open-angle glaucoma (POAG).
Methods: We performed a case-control study, and the patients recruited were classified into two groups, 1) 30 patients
with POAG (GG) and 2) 30 patients with cataracts (CG), who acted as the controls. Aqueous humor samples of each
patient were obtained by paracentesis at the beginning of the surgical procedures. 5-HT and 5-HIAA levels were
determined by high performance liquid chromatography (HPLC) with electrochemical detection.
Results: There were no statistical differences between age (71.3±7.2 years in GG, 73.5±9.0 years in CG; p=0.2581) or
gender (sex ratio 0.765 in GG and 0.667 in CG). 5-HT levels were lower in GG, but this difference was not significant
(p=0.820). We observed a statistically significant higher level of 5-HIAA in GG (p=0.001). The 5-HT turnover (5-HIAA/
5-HT) were higher in GG than in CG (p<0.05), but the difference was not significant (p=0.598).
Conclusions: The level of 5-HT was lower in GG patients, and the level of 5-HIAA was higher in GG patients than in
CG patients.
Glaucoma is one of the main causes of blindness, only
behind cataracts. Its prevalence in the world is 2.4%, and there
are  approximately  105  million  people  with  glaucoma
worldwide  [1,2].  This  disease  is  characterized  by  a
progressive  loss  of  ganglion  fibers,  which  involve  the
occurrence of the peripheral visual field loss [3].
There are many risk factors for glaucoma, and intraocular
pressure  (IOP)  is  the  most  important.  That  is  why  the
treatment for this optic neuropathy always was led to lowering
IOP [4]. Researchers have also been studying the mechanisms
of cell death in glaucoma, and presently it is known that the
treatment  against  ocular  hypertension  (OHT)  alone  is  not
sufficient to prevent glaucoma [5]. Protection against optic
nerve damage is also an important factor [6].
Apoptosis has been proven to occur to retinal ganglion
cells [7-9]. This mechanism of programmed cell death or cell
suicide is initiated when a cell is not necessary or is damaged.
It is a physiologic mechanism that allows the organisms to
eliminate these cells [10]. Abnormal increases of apoptosis
can lead to different disorders.
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An increased level of oxidative stress has been reported
in glaucomatous optic neuropathy [11,12]. Oxidative stress is
a result of imbalance between prooxidants and antioxidants.
So in these conditions there are high levels of free radicals that
act by damaging cells and can induce the retinal ganglion cell
death by apoptosis [13,14]. Glutamate toxicity has also been
involved in retinal ganglion cells (RGC) death, so even though
IOP is efficient controlled, RGC death will continue if toxic
effects of glutamate are not prevented [15,16].
Serotonin  is  another  molecule  that  is  involved  in  the
pathogenesis of glaucoma [17]. It is an indolamine, which is
a precursor of melatonin. The potential antioxidant capacity
of melatonin is well known [18,19], and there is evidence to
suggest  that  melatonin  could  decrease  the  intraocular
pressure. Therefore, melatonin could be used in glaucomatous
therapy [20]. It is also known that melatonin also has an
inhibitor effect on nitric oxide levels, so this molecule could
protect cells from nitrosative stress [21].
The study of serotonin, its metabolites, and their role in
glaucomatous optic neuropathy could be very important for
developing new strategies against this disease. For that reason,
we  have  studied  the  serotonin  (5-HT)  and  5-
hydroxiindolacetic  acid  (5-HIAA,  a  product  of  serotonin
degradation) levels in aqueous humor (AH) of patients with
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2143primary  open-angle  glaucoma  (POAG)  and  patients  with
cataracts (used as the comparative control group).
METHODS
A case-control study was performed in 60 eyes of 60 patients
who were selected from the Department of Ophthalmology of
Dr. Peset University Hospital (Valencia, Spain) and Punta de
Europa Hospital (Algeciras, Cadiz, Spain) according to the
inclusion/exclusion criteria (Table 1) and were classified into
two  groups,  1)  the  glaucoma  group,  which  consisted  of
patients with POAG (GG, n=30) and 2) the cataract group,
which consisted of patients with cataracts (CG, n=30).
The  Clinical  Research  Ethics  Committee  and  the
Research Committee of the Dr. Peset University Hospital
approved this study, which followed the Helsinki guidelines
for human research. In all glaucoma patients, the surgical
technique  used  was  Watson’s  trabeculectomy.  The
demographic characteristics of participants of both glaucoma
and cataract groups are shown in Table 2.
A sample of AH was obtained from each patient through
an anterior chamber paracentesis at the onset of the surgery
using a 27 gauge needle under an operating microscope with
special care to avoid contamination and was immediately
frozen  at  −85  °C  until  processing  at  IBMC-Instituto  de
Biologia Molecular e Celular (Porto, Portugal).
Tissue preparation: Human AH samples were diluted 1:3
v/v in 0.2N perchloric acid, filtered through a 0.2 μm Nylon
microfilter  (Costar,  Cambridge,  MA)  by  centrifugation
(10,000 rpm for 5 min at 4 °C), and immediately analyzed by
high performance liquid chromatography (HPLC).
High  performance  liquid  chromatography-
electrochemical  detection  equipment  and  conditions:  The
high  performance  liquid  chromatography  with
electrochemical detection (ECD) was applied according to a
modified method of Ali [22]. Analyses were performed using
a Gilson Medical Electronics HPLC system (Middleton, WI)
with a LC-234 auto-injector equipped with a LC307 delivery
pump  and  with  a  LC142  electrochemical  detector  under
reversed phase conditions with a Supelcosil LC 7.5 cm×4.6
cm, 3 mm column (Supelco; Sigma-Aldrich, Bellefonte, PA).
The software used was a 712 HPLC system controller data
version  1.30  management  (Gilson  Medical  Electronics).
Compounds were eluted isocratically over an 18 min runtime
at a flow rate of 1 ml/min. The mobile phase consisted of 70
mM potassium dihydrogen phosphate buffer (pH adjusted to
3.0 with phosphoric acid), 1 mM 1-hepatosulfonic acid, 107.5
mM sodium EDTA, and 10% methanol. Sample injection was
20 ml, and the electrochemical detector was recorded with a
glassy carbon working electrode set at +0.75 V.
Qualitative and quantitative analysis: Identification was
performed  by  comparison  with  standard  retention  times
determined by injections of standard mixture run at given
intervals between sample analyses. Capacity factor was not
considered  a  chromatographic  parameter  since  it  was  not
possible to determine the dead volume under the given HPLC
conditions.  Quantification  was  made  using  the  calibration
curve  standards  with  5-HT  (r=0.0004)  and  5-HIAA
(r=0.0003).  Samples  were  injected  in  duplicate,  and  the
amount of each compound was expressed in ng/ml of AH.
Statistical  analysis:  Data  were  analyzed  using  SPSS
program version 14.0 (SPSS Inc., Chicago, IL). Kolmogorov–
Smirnov  test  was  used  for  checking  the  normality.  Then,
Student’s  t-test  for  independent  samples  was  used  when
comparing results. Pearson’s correlation was used to check
the  correlation  between  variables.  The  statistic  level  of
significance was considered at p<0.05.
RESULTS
No  significant  age  differences  were  found  between  both
studied groups (71.3±7.2 years in GG, 73.5±9.0 years in CG;
p=0.2581) nor any significant gender differences (sex ratio
TABLE 1. EXCLUSION CRITERIA.
Glaucoma Cataracts
Glaucoma different of POAG Ocular pathology different of cataracts
Age under 41 or over 90 years Family history of glaucoma
Age under 41 or over 90 years
POAG=primary open-angle glaucoma.
TABLE 2. FEATURES OF THE STUDIED GROUPS.
Groups N
     Age
(mean±SD) Male Female SR
GG 30 71.267±7.182 13 (43%) 17 (57%) 0.765
CG 30 73.533±8.989 12 (40%) 18 (60%) 0.667
GG=glaucoma group; CG=cataract group; SD=standard deviation; SR=sex ratio (number of male/number of female).
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Gender0.765 in GG and 0.667 in CG; Table 2). We observed higher
levels of serotonin in the cataract group than in the glaucoma
group (Figure 1), but the difference was not significant (2.838
ng/ml in GG and 3.076 ng/ml in CG; p=0.820). Figure 2 shows
that 5-HIAA levels were statistically higher in GG than in CG
(22.317 ng/ml in GG and 18.816 ng/ml in CG; p=0.001). The
5-HT turnover (5-HIAA/5-HT) was higher in GG, but the
difference was not significant (14.050 ng/ml in GG and 12.684
ng/ml in CG; p=0.598; Figure 3). The correlation between 5-
HT  and  5-HIAA  was  assessed  by  means  of  Pearson’s
correlation (Figure 4 and Figure 5), and the levels of 5-HT and
5-HIAA were associated (glaucoma 5-HT/5-HIAA: Pearson=
−0.756; p=0.021; cataracts 5-HT/5-HIAA: Pearson=−0.613;
p=0.028).
DISCUSSION
Glaucoma is an optic neuropathy. Therefore, the study of
neurotransmitters  and  their  role  in  this  neurodegenerative
disorder  is  very  important  for  preventing  glaucomatous
blindness [23]. In this study, we have studied the levels of
serotonin in aqueous humor of patients with POAG.
Serotonin  is  a  neurotransmitter  that  is  synthesized  in
neurons  and  stored  into  vesicles.  It  is  present  in  the
mammalian eye, and its levels are higher in the iris-ciliary
body complex (ICBC) [24]. After a nervous impulse, 5-HT is
released in the synaptic cleft where it interacts with post-
synaptic receptors. There is evidence that serotonin plays a
role in the regulation of AH dynamics [25]. Seven types of
serotonin receptors have been identified (5-HT1 to 5-HT7).
The stimulation of 5-HT7 receptor causes an increase in IOP,
and the stimulation of 5-HT1A receptor causes a decrease in
IOP  [26,27].  On  the  other  hand,  5-HT  is  a  precursor  of
Figure 1. Serotonin levels. The chart shows lower levels of serotonin
in aqueous humor of glaucoma patients than in aqueous humor of
cataracts  patients  (2.838  ng/ml  in  GG  and  3.076  ng/ml  in  CG;
p=0.820).
melatonin,  a  hormone  where  its  concentration  varies
cyclically and plays a role in a variety of cellular processes
such as oxidative stress [28,29].
Oxidative stress is an imbalance between prooxidant and
antioxidant molecules and causes toxic effects that damage
proteins, lipids, and DNA [30]. It has been related to some
ocular diseases like cataracts, age macular degeneration, and
glaucoma [31-34].
Figure 2. 5-HIAA levels. The chart shows statistically significant
higher  levels  of  hydroxiindolacetic  acid  in  aqueous  humor  of
glaucoma  patients  than  in  aqueous  humor  of  cataracts  patients
(22.317 ng/ml in GG and 18.816 ng/ml in CG; p=0.001).
Figure 3. Serotonin turnover. The chart shows the 5-HIAA/5-HT
ratio in the aqueous humor of both glaucoma and cataract groups. 5-
HT  turnover  was  higher  in  glaucoma  patients  than  in  cataracts
patients (14.050 in GG and 12.684 in CG; p=0.598).
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antioxidant capacity of melatonin is well known, and there is
also evidence that melatonin could decrease IOP [35]. This
evidence  implies  that  melatonin  may  be  useful  in
glaucomatous optic neuropathy [36]. For that reason, we think
that 5-HT in POAG patients does not lead to the synthesis of
melatonin, but it is degraded by means of monoamine oxidase
enzyme (MAO) and the 5-HIAA levels would increase.
The  present  study  results  agree  with  this  hypothesis
because  we  have  observed  higher  levels  of  5-HIAA  in
Figure 4. Pearson’s correlation between 5-HT and 5-HIAA in the
glaucoma group. The chart shows a statistically significant negative
correlation  between  serotonin  and  hydroxiindolacetic  acid  in
glaucoma group (p=0.000).
Figure  5.  Pearson’s  correlation  between  5-HT  and  5-HIAA  in
cataract group. The chart shows a statistically significant negative
correlation  between  serotonin  and  hydroxiindolacetic  acid  in
cataracts group (p=0.002).
association with lower 5-HT levels in patients with POAG. In
addition, some authors have suggested that melatonin has
inhibitor  effects  on  nitric  oxide  levels  [37,38].  Therefore,
melatonin levels in these patients should be low. We have
evaluated in another study the nitric oxide levels in patients
with POAG, and the results have shown an increase of nitric
oxide with respect to the comparative group [37]. All these
findings showed the relation of 5-HT to the ethiopathogenic
mechanisms of primary open-angle glaucoma and could be
used in the design of new therapies for the early diagnosis and
prevention of glaucomatous blindness.
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